ConductScience.org, home

Paper41587271

Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification.

Armstrong A and 3 others. Circulation, 2026. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification. Papers, record 41587271. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41587271

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Current and Future Treatments for Takayasu Arteritis: Toward Cardiovascular Risk Modification.
PubMed
Journal
Circulation
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
3.92, provisional
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Armstrong AAlexandra
2Pugh DDan
3Basu NNeil
4Dhaun NNeerajhttps://orcid.org/0000-0001-9128-6603

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Takayasu ArteritisMajor topic
Immunosuppressive AgentsMajor topic
Cardiovascular DiseasesMajor topic
Humans
Heart Disease Risk Factors
Risk Factors
Female
Glucocorticoids
Animals

Source PubMed

Download CSV of topics

References121

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128811356Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis.J Rheumatol2017https://conductscience.org/library/papers/28811356PubMed
224511407Diagnosis and assessment of disease activity in takayasu arteritis: a childhood case illustrating the challenge.Case Rep Rheumatol2014https://conductscience.org/library/papers/24511407PubMed
324375298Optimizing the outcome of vascular intervention for Takayasu arteritis.Br J Surg2014https://conductscience.org/library/papers/24375298PubMed
437560375Common Autoantibody among Takayasu Arteritis and Ulcerative Colitis: A Possible Pathophysiology That Includes Gut-Vessel Connection in Vascular Inflammation.JMA J2023https://conductscience.org/library/papers/37560375PubMed
530824260Statins reduce relapse rate in Takayasu arteritis.Int J Cardiol2019https://conductscience.org/library/papers/30824260PubMed
617332971Mycophenolate mofetil reduces disease activity and steroid dosage in Takayasu arteritis.Clin Rheumatol2007https://conductscience.org/library/papers/17332971PubMed
738669786Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis.Semin Arthritis Rheum2024https://conductscience.org/library/papers/38669786PubMed
835126357Identification of the Association Between Toll-Like Receptors and T-Cell Activation in Takayasu's Arteritis.Front Immunol2021https://conductscience.org/library/papers/35126357PubMed
93918334018F-FDG-PET/MR imaging to monitor disease activity in large vessel vasculitis.Nat Commun2024https://conductscience.org/library/papers/39183340PubMed
1028385306Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging.J Am Coll Cardiol2017https://conductscience.org/library/papers/28385306PubMed
1136977782Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.Nat Rev Cardiol2023https://conductscience.org/library/papers/36977782PubMed
1229030659Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis.Rheumatol Int2017https://conductscience.org/library/papers/29030659PubMed
13363517052022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.Ann Rheum Dis2022https://conductscience.org/library/papers/36351705PubMed
1437011578Increased arterial stiffness and accelerated atherosclerosis in Takayasu arteritis.Semin Arthritis Rheum2023https://conductscience.org/library/papers/37011578PubMed
1533276814Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.Arthritis Res Ther2020https://conductscience.org/library/papers/33276814PubMed
1635354303Cerebrovascular Ischemic Events in Patients With Takayasu Arteritis.Stroke2022https://conductscience.org/library/papers/35354303PubMed
1738416140Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial.J Am Heart Assoc2024https://conductscience.org/library/papers/38416140PubMed
1824640521Impaired endothelial function in patients with Takayasu's arteritis.Acta Cardiol2014https://conductscience.org/library/papers/24640521PubMed
1928283361Incidence, prevalence, mortality and causes of death in Takayasu Arteritis in Korea - A nationwide, population-based study.Int J Cardiol2017https://conductscience.org/library/papers/28283361PubMed
2034257320Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis.Sci Rep2021https://conductscience.org/library/papers/34257320PubMed

See all 121 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42666711Childhood-Onset Takayasu Arteritis With Extensive Vascular Involvement: A Four-Decade Follow-Up Case Report.Case Rep Rheumatol2026https://conductscience.org/library/papers/42666711PubMed
42445657Secondary Hypertension and Renal Atrophy Unmasking Takayasu Arteritis With Renal Artery Stenosis.Cureus2026https://conductscience.org/library/papers/42445657PubMed
42399575Serum ferritin as a predictor of major adverse cardiovascular events in Takayasu arteritis: a two-center retrospective cohort study.Clin Rheumatol2026https://conductscience.org/library/papers/42399575PubMed
42305700Syncope as the Initial Presentation of Takayasu Arteritis in a 57-Year-Old Female: A Case Report and Literature Review.Clin Case Rep2026https://conductscience.org/library/papers/42305700PubMed
42125509Severe Neurovascular and Cardiovascular Manifestations of Takayasu Arteritis: A Case Series and Review of the Literature.Cureus2026https://conductscience.org/library/papers/42125509PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
MTOR2475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
NOTCH14851PubTator's text mininghttps://conductscience.org/library/genes/4851NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41587271

GET https://conductscience.org/api/papers/v1/41587271/references?page=2